Future Prospects for Stealth Liposomes in Cancer Therapy

ONCOLOGY

Volumn 11, Issue 10 SUPPL. 12, 1997, Pages 63-68

  Martin, Francis J ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOXORUBICIN; GEMCITABINE; LIPOSOME; MITOPODOZIDE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; STEALTH; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CONFERENCE PAPER; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KAPOSI SARCOMA; MICROENCAPSULATION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; VOMITING;

EID: 0030856275     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with Stealth liposomal doxorubicin (CAELYX): Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997.
2. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
3. Chrysogelos SA, Dickson RB: EGF receptor expression, regulation and function in breast cancer. Breast Cancer Res Treat 29:29-40, 1994.
4. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275:150-154, 1996.
5. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of PEG-LD in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
6. Hochster HS: Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer (suppl 5). Semin Oncol 22(2):55-59, 1995.
7. Gianni L, Munzone E, Capn G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
8. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
9. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982.
10. Gabizon A, Catane R, Uziely B, et al: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes. Cancer Res 54:987-992, 1994.
11. Berry G, Billingham M, Alderman E, et al: Reduced cardiotoxicity of PEG-LD (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control groups of cancer patients given doxorubicin. Proc Am Soc Clin Oncol 15:843, 1996.
12. Billingham ME, Mason JW, Brislow MR, et al: Anthracycline cardiomyopathy by morphologic changes. Cancer Treat Rep 62:865-872, 1978.
13. Loeher PJ, Einhorn LH: Drugs five years later: Cisplalin. Ann Intern Med 100:704-713, 1984.
14. Lelieveld P, van der Vijgh WJF, Veldhuizen RW, et al: Preclinical studies on toxicity, antitumor activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 20:1087-1104, 1984.
15. Mathe G, Kidani Y, Segiguchi M, et al: Oxalato-platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-Platinum and carboplatinum. Biomed Phannacother 43:237-250, 1989.
16. Schilder RJ, LaCreta FP, Ferez RP, et al: Phase I and pharmacokinetic study of ormaplatin (tctraplatin, NSC 363812) administered on a day 1 and 8 schedule. Cancer Res 54:709-717, 1994.
17. McKeage MJ, Mistry P, Ward J, et al: A phase I and pharmacology study of an oral platinum complex. JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Phannacol 36:451-458, 1995.
18. Kelland RL, McKeage MJ: New platinum agents. A comparison in ovarian cancer. Drugs Aging 5:85-95, 1994.
19. Steerenberg PA, Storm G, de Groot G, et al: Liposomes as a drug carrier system for cisdiamminedichloroplatinum (II). I. Binding capacity, stability and tumor growth inhibition in vitro. Int J Pharmaceutics 40:51-62, 1987.
20. Potkul RK, Gondal J, Bitterman P, et al: Toxicitics in rats with free versus liposomal encapsulated cisplatin. Am J Obstet Gynecol 164:652-658, 1991.
21. Ogilvie GK, Fettman MJ, Jameson VJ, et al: Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs. Am J Vet Res 53:1666-1669, 1992.
22. Layton D, Trouet A: A comparison of the therapeutic effects of free and liposomally encapsulated vincristine in leukemia mice. Eur J Cancer 16:949-950, 1980.
23. Allen TM, Newman MS, Woodle MC, et al: Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62:199-204, 1995.